Myo-Inositol for Infertility in PCOS
Myo-Inositol as an Adjuvant to Letrozole for Infertility in PolyCystic Ovary Syndrome (MALI-PCOS): a Randomized Pilot Trial
University of Oklahoma
168 participants
Feb 7, 2022
INTERVENTIONAL
Conditions
Summary
This will be a prospective, double-blind randomized clinical trial of letrozole and placebo versus letrozole and inositols for up to 5 treatment cycles of ovulation induction or until pregnancy is achieved. All participants and members of the research team will be blinded to the treatment arms. Placebo and inositol supplement will be packaged to appear the same, tested, and packaged by a commercial supply company. The inositols will be a 40:1 blend of myo-inositol and D-chiro inositol.
Eligibility
Inclusion Criteria6
- Female patient age 18-36
- Desire for pregnancy
- Diagnosis of oligo- or anovulation secondary to polycystic ovary syndrome -All subjects must have ovulatory dysfunction and at least one of the remaining two criteria:hyperandrogenism or polycystic ovarian morphology on ultrasound
- At least one patent fallopian tube
- Normal uterine cavity
- Male partner with sperm concentration of at least 14 million/mL in at least one ejaculate.
Exclusion Criteria6
- Cause of anovulation other than PCOS such as uncontrolled thyroid dysfunction or hyperprolactinemia
- Presence of another major infertility factor
- Diabetes
- Contraindication to pregnancy
- Myo-inositol use < 3 months prior to study enrollment
- Concomitant metformin use. Previous use is allowed with last use at least 6 weeks prior to randomization.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Inositol supplements given to inositol arm
Placebo supplement given to placebo arm
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04407754